Large gap with delayed quotes
|
Official
05/22/2026
-
17:35:06
|
Bid
05/22/2026 -
17:45:00
|
Bid Volume |
Ask
05/22/2026 -
17:45:00
|
Ask Volume |
|---|---|---|---|---|
|
100.80
+0.80
(
+0.80% )
|
100.70
|
5 |
100.80
|
64 |
Analysis date: 22.05.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 11.07.2025.
Interest
Very strong
Very strong
Four stars since 22.05.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 28.04.2026 at a price of 98.65.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 24.02.2026.
4wk Rel Perf
6.27%
6.27%
The four-week dividend-adjusted overperformance versus STOXX600 is 6.27%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 11.07.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.39%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.94%.
Mkt Cap in $bn
2.07
2.07
With a market capitalization between $2 & $8bn, PHARMA MAR is considered a mid-cap stock.
G/PE Ratio
2.12
2.12
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
8.41
8.41
The estimated PE is for the year 2028.
LT Growth
16.91%
16.91%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
9
9
Over the last seven weeks, an average of 9 analysts provided earnings per share estimates.
Dividend Yield
0.90%
0.90%
The twelve month estimated dividend yield represents 7.54% of earnings forecasts.
Beta
112
112
For 1% of index variation, the stock varies on average by 1.12%.
Correlation
0.38
0.38
Stock movements are strongly independent of index variations.
Value at Risk
23.95
23.95
The value at risk is estimated at EUR 23.95. The risk is therefore 23.76%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
02.01.2002
02.01.2002